Microbial associations for pneumonia causative agents and level of their resistance to antimicrobial drugs during a new coronavirus infection pandemic
- 作者: Kolotova O.N.1, Kataeva L.V.1, Vakarina A.A.1, Stepanova T.F.1, Stepanova K.B.1
-
隶属关系:
- Tyumen Region Infection Pathology Research Institute
- 期: 卷 13, 编号 6 (2023)
- 页面: 1069-1078
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/252307
- DOI: https://doi.org/10.15789/2220-7619-MAF-17541
- ID: 252307
如何引用文章
全文:
详细
Introduction. Bacterial coinfection and secondary bacterial infection are considered critical risk factors for the severity and mortality of SARS-CoV-2-caused pneumonia. The aim of the study was to analyze a pattern of microbial associations between K. pneumoniae and A. baumannii isolated from the lower respiratory tract discharge and sectional material (lung tissue) of patients diagnosed with pneumonia, and to compare resistance level in monoculture and associations during new coronavirus infection pandemic. Materials and methods. A bacteriological study of 2689 sputum and bronchial washing samples from patients at infectious diseases hospitals, and 1411 lung pathological material samples was carried out. Bacterial isolates were identified by mass spectrometry. Antibiotic sensitivity for isolates was determined by the disk diffusion method. Genetic determinants of resistance to beta-lactam antibiotics were detected by PCR. Statistical data processing was performed using SPSS version 22 software. Results. K. pneumoniae and A. baumannii isolates were predominantly found in two- and three-pathogen associations. It was established that the resistance level of K. pneumoniae isolates in association with A. baumannii is significantly higher compared to that in monoculture for all antimicrobial drugs studied. At the same time, K. pneumoniae in combination with Candida spp. vs monoculture showed significantly lower level of resistance to ciprofloxacin, amikacin, cefotaxime, ceftazidime and amoxicillin/clavulanic acid. K. pneumoniae isolates carried resistance determinants to extended-spectrum beta-lactamases: OXA-48 — (22.5%), OXA-51 — (5.6%), OXA-23 — (4.2%), KPC — 70.9%, NDM — 7%. Of these, 14.1% of strains had the ability to co-produce serine carbapenemases OXA-48 and KPC. Sputum and lung tissue A. baumannii isolates exhibited extremely high multiple resistance regardless of their associations with other microorganisms. Microbiome species similarity in the lower respiratory tract and lung tissue discharge was revealed. The proportion of lung tissue vs sputum resistant strains of K. pneumoniae and A. baumannii was significantly higher. Conclusion. The detection of of multiple drug resistant K. pneumoniae and A. baumannii isolates as well as their associations may indicate aggravated pneumonia severity.
作者简介
O. Kolotova
Tyumen Region Infection Pathology Research Institute
编辑信件的主要联系方式.
Email: Vakarinaaa@tniikip.rospotrebnadzor.ru
Junior Researcher, Bacteriological Labora
俄罗斯联邦, TyumenL. Kataeva
Tyumen Region Infection Pathology Research Institute
Email: Vakarinaaa@tniikip.rospotrebnadzor.ru
DSc (Medicine), Head Researcher, Head of the Bacteriogical Laboratory
俄罗斯联邦, TyumenA. Vakarina
Tyumen Region Infection Pathology Research Institute
Email: Vakarinaaa@tniikip.rospotrebnadzor.ru
PhD (Medicine), Senior Researcher, Bacteriogical Laboratory
俄罗斯联邦, TyumenT. Stepanova
Tyumen Region Infection Pathology Research Institute
Email: Vakarinaaa@tniikip.rospotrebnadzor.ru
DSc (Medicine), Professor, Director
俄罗斯联邦, TyumenK. Stepanova
Tyumen Region Infection Pathology Research Institute
Email: Vakarinaaa@tniikip.rospotrebnadzor.ru
PhD (Medicine), Leading Researcher, Laboratory of Clinics and Immunology of Biohelminthiasis
俄罗斯联邦, Tyumen参考
- Балмасова И.П., Малова Е.С., Сепиашвили Р.И. Вирусно-бактериальные коинфекции как глобальная проблема современной медицины // Вестник Российского университета дружбы народов. Серия: Медицина. 2018. Т. 1, № 22. С. 29–42. [Balmasova I.P., Malova E.S., Sepiashvili R.I. Viral and bacterial coinfection as a global problem of modern medicine. Vestnik Rossiiskogo universiteta druzhby narodov. Seriya: Meditsina = Bulletin of the Peoples’ Friendship University of Russia. Journal of Medicine, 2018, vol. 1, no. 22, pp. 29–42. (In Russ.)] doi: 10.22363/2313-0245-2018-22-1-29-42
- Зайратьянц О.В., Самсонова М.В., Черняев А.Л., Мишнев О.Д., Михалева Л.М., Крупнов Н.М., Калинин Д.В. Патологическая анатомия COVID-19: опыт 2000 аутопсий // Судебная медицина. 2020. Т. 6, № 4. С. 10–23. [Zayratyants O.V., Samsonova M.V., Cherniaev A.L., Mishnev O.D., Mikhaleva L.M., Krupnov N.M., Kalinin D.V. COVID-19 pathology: experience of 2000 autopsies. Sudebnaya meditsina = Forensic Medicine, 2020, vol. 6, no. 4, pp. 10–23. (In Russ.)] doi: 10.19048/fm340
- Землянко О.М., Рогоза Т.М., Журавлева Г.А. Механизмы множественной устойчивости бактерий к антибиотикам // Экологическая генетика. 2018. Т. 3, № 16. С. 4–17. [Zemlyanko O.M., Rogoza T.M., Zhuravleva G.A. Mechanisms of bacterial multiresistance to antibiotics. Ekologicheskaya genetika = Environmental genetics, 2018, vol. 3, no. 16, pp. 4–17. (In Russ.)] doi: 10.17816/ecogen1634-17
- Кисиль О.В., Ефименко Т.А., Габриэлян Н.И. Ефременкова О.В. Разработка методов антимикробной терапии, преодолевающих антибиотикорезистентность Acinetobacter baumannii // Acta Naturae. 2020. Т. 12, № 3. C. 34–45. [Kisil O.V., Efimenko T.A., Gabrielyan N.I., Efremenkova O.V. Development of antimicrobial therapy methods to overcome the antibiotic resistance of Acinetobacter baumannii. Acta Naturae, 2020, vol. 12, no. 3, pp. 34–45. (In Russ.)] doi: 10.32607/actanaturae.10955
- Левченко К.В., Бондаренко В.Н., Мицура В.М., Тапальский Д.В. Вирусно-бактериальная пневмония при COVID-19: клинико-лабораторная характеристика пациентов и спектр бактериальных возбудителей // Проблемы здоровья и экологии. 2023. Т. 20, № 2. С. 27–34. [Levchenko K.V., Bondarenko V.N., Mitsura V.M., Tapalski D.V. Viral-bacterial pneumonia in COVID-19: clinical and laboratory characteristics of patients and a spectrum of bacterial pathogens. Problemy zdorov’ya i ekologii = Health and Ecology Issues, 2023, vol. 20, no. 2, pp. 27–34. (In Russ.)] doi: 10.51523/2708-6011.2023-20-2-04
- Митрохин С.Д., Орлова О.Е., Янковская О.С., Гостева И.В., Галицкий А.А., Карпова И.В., Ведяшкина С.Г., Шкода А.С. Опыт применения антибактериальной терапии у пациентов с новой коронавирусной инфекцией COVID-19 на госпитальном этапе лечения (предварительные итоги и рекомендации) // Клиническая микробиология и антимикробная химиотерапия. 2022. Т. 24, № 2. С. 181–192. [Mitrokhin S.D., Orlova O.E., Yankovskaya O.S., Gosteva I.V., Galitsky A.A., Karpova I.V., Vedyashkina S.G., Skoda A.S. Real-life antimicrobial therapy in hospitalized patients with COVID-19 (preliminary results and recommendations. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy, 2022, vol. 24, no. 2, pp. 181–192. (In Russ.)] doi: 10.36488/cmac.2022.2.181-192
- Ортенберг Э.А. Почти два года с COVID-19: новые аспекты использования антибиотиков // Клиническая микробиология и антимикробная химиотерапия. 2021. Т. 23, № 3. С. 246–251. [Ortenberg E.A. Almost two years with COVID-19: some aspects of antibiotic use. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy, 2021, vol. 23, no. 3, pp. 246–251. (In Russ.)] doi: 10.36488/cmac.2021.3.248-253
- Ромашов О.М., Ни О.Г., Быков А.О., Круглов А.Н., Проценко Д.Н., Тюрин И.Н. Оценка резистентности микроорганизмов многопрофильного стационара и модернизация схем антимикробной терапии в условиях пандемии COVID-19-инфекции // Клиническая микробиология и антимикробная химиотерапия. 2021. Т. 23, № 3. С. 293–303. [Romashov O.M., Ni O.G., Bykov A.O., Kruglov A.N., Protsenko D.N., Tyurin I.N. Antimicrobial resistance and antimicrobial therapy modification during COVID19 pandemic in large tertiary hospital. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya = Clinical Microbiology and Antimicrobial Chemotherapy, 2021, vol. 23, no. 3, pp. 293–303. (In Russ.)] doi: 10.36488/cmac.2021.3.293-303
- Тапальский Д.В., Карпова Е.В., Акуленок О.М., Окулич В.К., Генералов И.И., Лескова Н.Ю., Антонова Е.Г., Жильцов И.В., Осипкина О.В., Можаровская Л.В., Баранов О.Ю. Антибиотикорезистентность Klebsiella pneumoniae на фоне пандемии COVID-19: опыт многопрофильного стационара // Инфекционные болезни: новости, мнения, обучение. 2021. Т. 10, № 3. С. 15–22. [Tapalsky D.V., Karpova E.V., Akulenok O.M., Okulich V.K., Generalov I.I., Leskova N.Yu., Antonova E.G., Zhiltsov I.V., Osipkina O.V., Mozharovskaya L.V., Baranov O.Yu. Antibiotic resistance of Klebsiella pneumoniae against the background of the COVID-19 pandemic: experience of the multidisciplinary hospital. Infekcionne bolezni: novosti, mnenija, obuchenie = Infectious Diseases: News, Opinions, Training, 2021, vol. 10, no. 3, pp. 15–22. (In Russ.)] doi: 10.33029/2305-3496-2021-10-3-15-22
- Appaneal H.J., Lopes V.V., LaPlante K.L., Caffrey A.R. Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with Acinetobacter baumannii infection. Antimicrob. Agents Chemother., 2022, vol. 66, no. 3: e0197521. doi: 10.1128/AAC.01975-21
- Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020, no. 395, pp. 507–513. doi: 10.1016/S0140-6736(20)30211-7
- Chen X., Liao B., Cheng L., Peng X., Xu X., Li Y., Hu T., Li J., Zhou X., Ren B. The microbial coinfection in COVID-19. Appl. Microbiol. Biotechnol., 2020, vol. 104, no. 18, pp. 7777–7785. doi: 10.1007/s00253-020-10814-6
- Clancy C.J., Schwartz I.S., Kula B., Nguyen M.H.. Bacterial superinfections among persons with Coronavirus disease 2019: a comprehensive review of data from postmortem studies. Open Forum Infect. Dis., 2021, vol. 8, no. 3: ofab065. doi: 10.1093/ofid/ofab065
- Cohen R., Babushkin F., Finn T., Geller K., Alexander H., Datnow C., Uda M., Shapiro M., Paikin S., Lellouche J. High rates of bacterial pulmonary co-infections and superinfections identified by multiplex PCR among critically ill COVID-19 patients. Microorganisms, 2021, vol. 9, no. 12: 2483. doi: 10.3390/microorganisms9122483
- Hasani A., Soltani E., Ahangarzadeh Rezaee M., Pirzadeh T., Ahangar Oskouee M., Hasani A., Gholizadeh P., Oskouie A.N., Binesh E. Serotyping of Klebsiella pneumoniae and its relation with capsule-associated virulence genes, antimicrobial resistance pattern, and clinical infections: a descriptive study in medical practice. Infect. Drug. Resist., 2020, no. 13, pp. 1971—1980. doi: 10.2147/IDR.S243984
- Hughes S., Troise O., Donaldson H., Mughal N., Moore L.S.P. Bacterial and fungal coinfection among hospitalised patients with COVID-19: a retrospective cohort study in a UK secondary care setting. Clin. Microbiol. Infect., 2020, vol. 26, no. 10, pp. 1395–1399. doi: 10.1016/j.cmi.2020.06.025
- Lai C.C., Wang C.Y., Hsueh P.R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? J. Microbiol. Immunol. Infect., 2020, vol. 53, no. 4, pp. 505–512. doi: 10.1016/j.jmii.2020.05.013
- Marua A.M., Shethwala N.D., Bhatt P., Shah A. Evaluation of bacterial co-infections and antibiotic resistance in positive COVID-19 patients. Maedica (Bucur), 2022, vol. 17, no. 2, pp. 350–356. doi: https://doi: 10.26574/maedica.2022.17.2.350.
- May L., Klein E.Y., Rothman R.E., Laxminarayan R. Trends in antibiotic resistance in coagulase-negative staphylococci in the United States, 1999 to 2012. Antimicrob. Agents Chemother., 2014, vol. 3, no. 58, pp. 1404–1409. doi: 10.1128/AAC.01908-13
- Mirzaei R., Goodarzi P., Asadi M., Soltani A., Aljanabi H.A.A., Jeda A.S., Dashtbin S., Jalalifar S., Mohammadzadeh R., Teimoori A., Tari K., Salari M., Ghiasvand S., Kazemi S., Yousefimashouf R., Keyvani H., Karampoor S. Bacterial co-infections with SARS-CoV-2. IUBMB Life, 2020, vol. 72, no. 10, pp. 2097–2111. doi: 10.1002/iub.2356
- Munier A.L., Biard L., Legrand M., Rousseau C., Lafaurie M., Donay J.L., Flicoteaux R., Mebazaa A., Mimoun M., Molina J.M. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int. J. Infect. Dis., 2019, no. 79, pp. 179–184. doi: 10.1016/j.ijid.2018.11.371
- Nafsa A., Maiesha S.M., Ullah M.A., Araf Y., Rahaman T.I., Moin A.T., Hosen M.J. COVID-19-associated candidiasis: possible patho-mechanism, predisposing factors, and prevention strategies. Curr. Microbiol., 2022, vol. 79, no. 5: 127. doi: 10.1007/s00284-022-02824-6
- Rawson T.M., Moore L.S.P., Zhu N., Ranganathan N., Skolimowska K., Gilchrist M., Satta G., Cooke G., Holmes A. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin. Infect. Dis., 2020, vol. 71, no. 9, pp. 2459–2468. doi: 10.1093/cid/ciaa530
- Santella B., Serretiello E., De Filippis A., Folliero V., Iervolino D., Dell’Annunziata F., Manente R., Valitutti F., Santoro E., Pagliano P., Galdiero M., Boccia G., Franci G. Lower respiratory tract pathogens and their antimicrobial susceptibility pattern: a 5-year study. Antibiotics, 2021, no. 10: 851. doi: 10.3390/antibiotics10070851
- Teng G., Wang N., Nie X., Zhang L., Liu H. Analysis of risk factors for early-onset ventilator-associated pneumonia in a neurosurgical intensive care unit. BMC Infect. Dis., 2022, no. 22: 66. doi: 10.1186/s12879-022-07053-7
- Torres A., Cilloniz C., Niederman M.S., Menéndez R., Chalmers J.D., Wunderink R.G., Poll T. Pneumonia. Nat. Rev. Dis. Primers, 2021, no. 7, pp. 25. doi: 10.1038/s41572-021-00259-0
- Ulu-Kilic A., Gundogdu A., Cevahir F., Kilic H., Gunes T., Alp E. An outbreak of bloodstream infection due to extensively resistant Acinetobacter baumannii among neonates. Am. J. Infect. Control, 2018, vol. 46, no. 2, pp. 154–158. doi: 10.1016/j.ajic.2017.08.007
- Wu H.Y., Chang P.H., Chen K.Y., Lin I.F., Hsih W.H., Tsai W.L., Chen J.A., Lee S.S.; GREAT working group. Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: incidence, diagnosis and treatment. J. Microbiol. Immunol. Infect., 2022, vol. 55, no. 6, pp. 985–992. doi: 10.1016/j.jmii.2022.09.006
补充文件
